Our Story

We are a leading innovative oncology molecular diagnostics and testing company in China. Our proprietary technology spans the full spectrum of molecular testing, and we lead the competition in China in adopting a multi-omics approach that enables the comprehensive testing for cancer risk, early detection, therapy selection, and monitoring for cancer relapse.

Senior Management

Qualifications

Inspection institute qualification
Corporate certificate
<
ISO15189 Accredited
<
CAP Accredited
<
SCCL EQA Certificate
<
SCCL EQA Certificate
<
SCCL EQA Certificate
<
Jiangsu Certification for EQA
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
High-tech Enterprise.
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
Jiangsu Certification for EQA
<
Jiangsu Certification for EQA
<
Jiangsu Certification for EQA
<
SCCL EQA Certificate
<
NCCL EQA Certificate
<
JIANGSU CERTIFICATION FOR EQA
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
CAP Accredited
<
High-tech Enterprise.
<
Zhongguancun High-tech Enterprise.
<
NGS Qualification
<
ARMS Qualification
<
High-tech Enterprise.
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
SCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate
<
NCCL EQA Certificate

History

2014/11

Genecast Biotechnology was established in the PRC.

2016/01

We launched Genecast Comprehensive.

2017/06

We launched Genecast PD-L1.

2017/07

We launched Genecast Lung and Genecast CRC.

2017/12

We were awarded National High-tech Enterprise Certificate.

2018/04

Wuxi Genecast Laboratory obtained the Practice License of Medical Institution.

2018/09

We launched MammaPrint® licensed from Agendia in China.

2018/10

Wuxi laboratory was certified by U.S. College of American Pathologist.

2018/12

Taizhou manufacturing facility obtained the YY/T0287- 2017 idt ISO 13485:2016 certification.

2019/09

Wuxi laboratory was certified as a PCR laboratory to carry out “tumor-related genetic testing activities (with conventional ARMS method and NGS method)”.

2019/09

Awarded 2019 EY Fudan China Most Promising Enterprises Award by Ernst & Young.

2019/11

We launched Genecast Lung TILs.

2020/04

We launched Genecast RNA Fusion Focus.

2020/11

We launched Genecast MRD – Lung.

2020/11

We launched TumorX with the participation of Zhejiang University.

2021/02

We obtained our first IVD product registration certificate from NMPA for Genecast IVD – KNBP.

2021/07

We launched Genecast Genius G1 and Genecast INTEGRO V1.0, both certified by NMPA.

2021/11

We launched Tissue of Origin® in China.

2022/02

We launched Genecast MRD – CRC.

2022/03

We obtained CE marking for 5 Genecast IVD products.

2022/06

We launched Genecast MRD – Comprehensive.

2022/07

Our new Taizhou manufacturing facility commenced operations.

2022/08

We received a Class II medical device registration certificate from Jiangsu MPA for our Genecast Genius X.

2022/08

Established a strategic partnership with Tianjin Pilot Free Trade Zone International Innovative Personalized Medical Research Institute

2014/11

Genecast Biotechnology was established in the PRC.

2016/01

We launched Genecast Comprehensive.

2017/06

We launched Genecast PD-L1.

2017/07

We launched Genecast Lung and Genecast CRC.

2017/12

We were awarded National High-tech Enterprise Certificate.

2018/04

Wuxi Genecast Laboratory obtained the Practice License of Medical Institution.

2018/09

We launched MammaPrint® licensed from Agendia in China.

2018/10

Wuxi laboratory was certified by U.S. College of American Pathologist.

2018/12

Taizhou manufacturing facility obtained the YY/T0287- 2017 idt ISO 13485:2016 certification.

2019/09

Wuxi laboratory was certified as a PCR laboratory to carry out “tumor-related genetic testing activities (with conventional ARMS method and NGS method)”.

2019/09

Awarded 2019 EY Fudan China Most Promising Enterprises Award by Ernst & Young.

2019/11

We launched Genecast Lung TILs.

2020/04

We launched Genecast RNA Fusion Focus.

2020/11

We launched Genecast MRD – Lung.

2020/11

We launched TumorX with the participation of Zhejiang University.

2021/02

We obtained our first IVD product registration certificate from NMPA for Genecast IVD – KNBP.

2021/07

We launched Genecast Genius G1 and Genecast INTEGRO V1.0, both certified by NMPA.

2021/11

We launched Tissue of Origin® in China.

2022/02

We launched Genecast MRD – CRC.

2022/03

We obtained CE marking for 5 Genecast IVD products.

2022/06

We launched Genecast MRD – Comprehensive.

2022/07

Our new Taizhou manufacturing facility commenced operations.

2022/08

We received a Class II medical device registration certificate from Jiangsu MPA for our Genecast Genius X.

2022/08

Established a strategic partnership with Tianjin Pilot Free Trade Zone International Innovative Personalized Medical Research Institute

Careers

We are a leading innovative oncology molecular diagnostics and testing company in China. Our proprietary technology spans the full spectrum of molecular testing, and we lead the competition in China in adopting a multi-omics approach that enables the comprehensive testing for cancer risk, early detection, therapy selection, and monitoring for cancer relapse.   

Email :zhaopin@genecast.com.cn

Job Responsibilities
  • ·  

    MSL 

  • ·  Sales Representative
  • ·  Product Manager
  • ·  Medical Advisor
  • ·  Account Manager
  • ·  

    Technical Support Specialist

Contact Us

We are committed to being improve the leader in the quality of life of cancer patients.